Clinical Trials Logo

Clinical Trial Summary

This is a cross-sectional cohort study of metastatic GastroIntestinal Stromal Tumor (GIST) patients on imatinib for ≥ 10 years included in EORTC trial 62005-STBSG entitled "Phase 3 randomized, intergroup, international tiral assessing the clinical activity of STI-571 at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumor (GIST) expressing the KIT receptor tyrosine kinase (CD117) - NCT00685828". With this study, the aim is to identify patient characteristics, tumour characteristics, treatment factors and quality of life outcomes associated with prolonged treatment with imatinib and/or prolonged survival. This observational study will further help to put in place a questionnaire to evaluate patients quality of life with prolonged imatinib treatment, that will then be used in a prospective study.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04097093
Study type Observational [Patient Registry]
Source European Organisation for Research and Treatment of Cancer - EORTC
Contact
Status Withdrawn
Phase
Start date June 1, 2020
Completion date June 1, 2021

See also
  Status Clinical Trial Phase
Recruiting NCT05957367 - A Study of DCC-3116 in Combination With Anticancer Therapies in Participants With Advanced Malignancies Phase 1/Phase 2
Completed NCT01770405 - Clinical Registry of nCLE in Masses and Cystic Tumors of the Pancreas, Lymph Nodes, Submucosal Lesions of the GI Tract N/A
Active, not recruiting NCT03556384 - Temozolomide (TMZ) In Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST) Phase 2
Recruiting NCT05895942 - Exploring the Molecular Mechanism Based on KIT Mutation
Completed NCT01459757 - Non-Interventional Retrospective Correlation Of Tumor Mutational Status To Clinical Benefit Of GIST Patients Treated With Sunitinib N/A
Completed NCT00979381 - Study of the Immunoresponse in Patients Treated With a Tyrosine Kinase Inhibitor N/A
Completed NCT00399152 - Perifosine + Sunitinib Malate for Patients With Advanced Cancers Phase 1
Recruiting NCT03715933 - Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas Phase 1
Completed NCT04599660 - Study in Low Risk Gastrointestinal Stromal Tumor (GISTs)
Completed NCT05400018 - Clinical Evaluation of Genetron D842V PCR Kit in GIST Patients
Recruiting NCT03475953 - A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors Phase 1/Phase 2
Not yet recruiting NCT06208748 - SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST Phase 2
Not yet recruiting NCT04825470 - Liver Transplantation for Unresectable GIST Liver Metastases N/A
Recruiting NCT00687778 - 11C-Acetate PET/CT Non-FDG-Avid Tumors N/A
Completed NCT00979329 - Study on the Influence of Sunitinib and Sorafenib on Fatigue, QoL, Depression in Patients With Metastatic RCC or GIST N/A
Active, not recruiting NCT04927260 - French Long Term Registry With Longitudinal Follow up of PDGFRA D842V-GIST Patients
Completed NCT03465722 - (VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST Phase 3
Completed NCT03880617 - Distress, Medication Adherence and Care Needs in Patients With CML and GIST Receiving Oral Targeted Therapy
Recruiting NCT03896958 - The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)
Completed NCT01323400 - Efficacy of Pazopanib in Gastrointestinal Stromal Tumors (GIST) Phase 2